Aliases & Classifications for Neuritis

MalaCards integrated aliases for Neuritis:

Name: Neuritis 12 54 44 15 70
Peripheral Neuritis 12 6

Classifications:



External Ids:

Disease Ontology 12 DOID:1803
MeSH 44 D009443
NCIt 50 C116381
SNOMED-CT 67 247378004
UMLS 70 C0027813

Summaries for Neuritis

MalaCards based summary : Neuritis, also known as peripheral neuritis, is related to optic neuritis and acute retrobulbar neuritis, and has symptoms including sciatica and neuralgia. An important gene associated with Neuritis is NEFL (Neurofilament Light Chain), and among its related pathways/superpathways are Lung fibrosis and Neural Crest Differentiation. The drugs Acetylcholine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and t cells, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Neuritis (/njʊəˈraɪtɪs/) is inflammation of a nerve or the general inflammation of the peripheral... more...

Related Diseases for Neuritis

Diseases related to Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 813)
# Related Disease Score Top Affiliating Genes
1 optic neuritis 33.5 TNF MT-ND4 MPZ MBP
2 acute retrobulbar neuritis 32.9 MT-ND4 MBP
3 optic nerve disease 32.2 TNF NEFL MT-ND4 MBP
4 amyotrophic neuralgia 32.1 PMP22 MPZ
5 guillain-barre syndrome 31.8 TNF PMP22 PMP2 MPZ MBP
6 allergic encephalomyelitis 31.7 MBP CCL5
7 demyelinating disease 31.7 TNF PMP22 MPZ MBP CCL5 CCL4
8 multiple sclerosis 31.5 TNF NEFL MPZ MBP CCL5 CCL4
9 acute disseminated encephalomyelitis 31.4 MPZ MBP CCL4
10 relapsing-remitting multiple sclerosis 31.2 TNF MBP CCL5
11 polyradiculoneuropathy 31.1 PMP22 MPZ MBP CCL5 CCL4
12 meningoencephalitis 31.1 TNF MBP CCL5
13 chronic inflammatory demyelinating polyradiculoneuropathy 31.0 PMP22 MPZ MBP CCL5 CCL4
14 meningitis 30.9 TNF CCL5 CCL4
15 mononeuropathy 30.7 TNF PMP22 MPZ
16 polyneuropathy 30.7 TNF PMP22 MPZ MBP LMNA GJB1
17 myasthenia gravis 30.5 TNF MBP CHRNG
18 viral encephalitis 30.3 TNF MBP CCL5
19 dengue disease 30.3 TNF CCL5 CCL4
20 brachial plexus neuropathy 30.3 PMP22 MPZ GJB1
21 autoimmune neuropathy 30.2 PMP2 MPZ
22 neuropathy, hereditary, with liability to pressure palsies 30.1 PMP22 MPZ GJB1
23 foot drop 30.1 PMP22 MPZ
24 sensory peripheral neuropathy 29.9 SPTLC3 PMP22 MPZ GJB1
25 hypertrophic neuropathy of dejerine-sottas 29.9 PMP22 NEFL MPZ MBP GJB1
26 sensorineural hearing loss 29.9 TNF PMP22 PEX6 IARS2 HARS1 GJB1
27 axonal neuropathy 29.8 PMP22 NEFL LMNA
28 charcot-marie-tooth disease, demyelinating, type 1a 29.7 PMP22 NEFL MPZ GJB1
29 hereditary neuropathies 29.7 PMP22 MPZ MBP LMNA GJB1
30 neuropathy, congenital hypomyelinating, 1, autosomal recessive 29.3 PMP22 PMP2 NEFL MPZ LMNA GJB1
31 neuromuscular disease 29.2 PMP22 NEFL MPZ LMNA GJB1 CHRNG
32 charcot-marie-tooth disease 28.9 PMP22 PMP2 NEFL MPZ MBP LMNA
33 tooth disease 28.9 TNF PMP22 PMP2 NEFL MPZ MBP
34 neuropathy 27.6 TNF SPTLC3 PMP22 PMP2 PEX6 NGLY1
35 peripheral nervous system disease 27.1 TNF SPTLC3 PMP22 PMP2 PEX6 NGLY1
36 amyotrophy, hereditary neuralgic 11.5
37 vestibular neuronitis 11.4
38 neuromyelitis optica 11.4
39 brachial plexus neuritis 11.3
40 parsonage turner syndrome 11.3
41 chronic relapsing inflammatory optic neuropathy 11.3
42 flynn-aird syndrome 11.2
43 autoimmune optic neuritis 11.1
44 labyrinthitis 11.1
45 isolated optic neuritis 11.1
46 optic neuritis with anti-mog antibodies 11.0
47 motor peripheral neuropathy 11.0
48 isolated optic neuritis without anti-mog antibodies 11.0
49 nutritional optic neuropathy 10.9
50 radiation induced brachial plexopathy 10.9

Graphical network of the top 20 diseases related to Neuritis:



Diseases related to Neuritis

Symptoms & Phenotypes for Neuritis

UMLS symptoms related to Neuritis:


sciatica; neuralgia

GenomeRNAi Phenotypes related to Neuritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.64 GJB1
2 Decreased viability GR00055-A-2 9.64 GJB1
3 Decreased viability GR00106-A-0 9.64 IARS2
4 Decreased viability GR00240-S-1 9.64 LMNA
5 Decreased viability GR00249-S 9.64 COX6A1 GJB1 LMNA MPZ NGLY1 SPTLC3
6 Decreased viability GR00381-A-1 9.64 MPZ
7 Decreased viability GR00381-A-3 9.64 MPZ
8 Decreased viability GR00386-A-1 9.64 IARS2 LMNA MPZ NEFL
9 Decreased viability GR00402-S-2 9.64 GJB1 IARS2 MBP MPZ TNF

MGI Mouse Phenotypes related to Neuritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.73 CHRNG COX6A1 DNAJB5 GJB1 HFE LMNA
2 nervous system MP:0003631 9.36 CHRNG COX6A1 GJB1 HFE LMNA MBP

Drugs & Therapeutics for Neuritis

Drugs for Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
5 (T,G)-A-L Phase 4
6
Glatiramer Acetate Phase 4 147245-92-9 3081884
7 Neurotransmitter Agents Phase 4
8 Cholinergic Agents Phase 4
9 Botulinum Toxins Phase 4
10 Adrenocorticotropic Hormone Phase 4
11 Antineoplastic Agents, Hormonal Phase 4
12
Simvastatin Approved Phase 3 79902-63-9 54454
13
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
14
Interferon beta-1b Approved Phase 2, Phase 3 145155-23-3
15 Anticholesteremic Agents Phase 3
16 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
17 Lipid Regulating Agents Phase 3
18 Hypolipidemic Agents Phase 3
19 Epoetin alfa Phase 3 113427-24-0
20 Hematinics Phase 3
21 Immunoglobulins Phase 3
22 Antibodies Phase 3
23 Immunoglobulins, Intravenous Phase 3
24 gamma-Globulins Phase 3
25 Rho(D) Immune Globulin Phase 3
26 Ginkgo Phase 3
27 Pharmaceutical Solutions Phase 3
28 Analgesics, Non-Narcotic Phase 2, Phase 3
29 Analgesics Phase 2, Phase 3
30 Cyclooxygenase Inhibitors Phase 2, Phase 3
31 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
32 Fingolimod Hydrochloride Phase 2, Phase 3
33
Hydrochlorothiazide Approved, Vet_approved Phase 2 58-93-5 3639
34
Amiloride Approved Phase 2 2016-88-8, 2609-46-3 16231
35
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
36
Clemastine Approved, Investigational Phase 2 15686-51-8 26987
37
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
38
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
39
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
40
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
41
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
42 Sodium Chloride Symporter Inhibitors Phase 2
43 Amiloride, hydrochlorothiazide drug combination Phase 2
44 Antihypertensive Agents Phase 2
45 Sodium Channel Blockers Phase 2
46 diuretics Phase 2
47 Diuretics, Potassium Sparing Phase 2
48 Anticonvulsants Phase 2
49 Antibodies, Monoclonal Phase 2
50 Trace Elements Phase 2

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS Unknown status NCT00910598 Phase 4 glatiramer acetate
2 Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10) Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
3 Probe Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome Completed NCT00241215 Phase 4 Botulinum toxin serotype A
4 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Recruiting NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV methylprednisolone (steroids)
5 Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation Recruiting NCT03247413 Phase 4 Dexamethasone 4 mg/ml;Normal saline
6 An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
7 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
8 Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial Unknown status NCT00261326 Phase 3 simvastatin;placebo
9 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study Unknown status NCT02220244 Phase 3 MD1003 100mg capsule
10 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed NCT00000117 Phase 3 Immunoglobulin
11 Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis Completed NCT01337986 Phase 2, Phase 3 Dalfampridine/Placebo;Placebo/Dalfampridine
12 Recovery of Demyelinating Optic Neuritis After Treatment With Equivalent High Doses of Oral vs. Intravenous Corticosteroids: a Randomized Single Blinded Clinical Trial Completed NCT01524250 Phase 2, Phase 3 corticosteroids;corticosteroids
13 Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Completed NCT01962571 Phase 3 Erythropoietin alfa;Placebo
14 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON) Completed NCT00856635 Phase 3 Glatiramer Acetate;placebo
15 The Efficacy of Steroid Therapy in Vestibular Neuritis Confirmed by Head Impulse Test: Prospective Randomized Controlled Study Completed NCT02098330 Phase 3 Ginkgo biloba & Methylprednisolone;Ginkgo biloba
16 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Multifocal Motor Neuropathy. Completed NCT01827072 Phase 3 NPB-01
17 A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multifocal Motor Neuropathy Completed NCT00666263 Phase 3
18 Hypoalgesic Effect of Median Nerve Neural Mobilization Versus Ibuprofen Pharmacologic Treatment in Patients With Cervicobrachial Pain Completed NCT02593721 Phase 2, Phase 3 Ibuprofen
19 Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis Terminated NCT01647880 Phase 2, Phase 3 Verum arm receiving Gilenya®;Active Comparator receiving Extavia®
20 The Investigation Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography Unknown status NCT01465893 Phase 2 Vitamin D;Vitamin D withheld
21 A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis Unknown status NCT01879527 Phase 2 Amiloride hydrochlorothiazide;Sugar pill
22 Double Blind, Placebo-controlled Study to Determine the Safety and Efficacy of Erythropoietin as an add-on Therapy of Methylprednisolone in Subjects With Acute Optic Neuritis (VISION PROTECT) Completed NCT00355095 Phase 2 Erythropoietin
23 A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis Completed NCT01802489 Phase 2 Amiloride;Placebo
24 A Phase II Double Blind, Randomized, Placebo Controlled Trial of Neuroprotection With Phenytoin in Acute Optic Neuritis Completed NCT01451593 Phase 2 Phenytoin;Placebo
25 A Multicenter, Follow-Up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201 Completed NCT02657915 Phase 2 Placebo;BIIB033 100mg/Kg
26 A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis Completed NCT01721161 Phase 2 Placebo
27 Visual Reconstitution Therapy After Optic Neuritis Completed NCT01274702 Phase 2
28 a Phase II Double Blind, Randomized, Placebo Controlled Trial of Effect of Phenytoin on the Ganglion Cell Inner Plexiform Layer (GCIPL) Thickness and Visual Field in Patients With a First Episode of Acute Optic Neuritis Completed NCT02939937 Phase 2 Phenytoin;placebo
29 A Controlled Cross-Over Trial of Subcutaneous Versus Intravenous Immunoglobulin for Multifocal Motor Neuropathy Completed NCT00268788 Phase 2 Subcutaneous immunoglobulin;Intravenous immunoglobulin
30 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
31 A Multicentre Study of Subcutaneous Immunoglobulin (SCIG) in Patients With Multifocal Motor Neuropathy (MMN) Completed NCT00701662 Phase 2
32 Randomized, Single-blind, Cross-over Study Investigating the Non-inferiority of Efficacy and Safety of HyQvia in Comparison With Conventional Subcutaneous Ig Therapy in Multifocal Motor Neuropathy Completed NCT02556437 Phase 2 HyQvia;Subcuvia
33 A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis Completed NCT00772525 Phase 2 Nerispirdine;Placebo
34 A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis Recruiting NCT02521311 Phase 2 Clemastine;Placebo
35 A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis Recruiting NCT03536559 Phase 2 CNM-Au8;Placebo
36 A Two-arm, Randomized, Double-blind, Placebocontrolled, Monocentric Study to Evaluate the Safety and Tolerability of ACT-01 Compared to Placebo in Patients With Acute Optic Neuritis Recruiting NCT04762017 Phase 2 ACT-01 IV administration
37 A Phase II Trial of High-Dose Vitamin D Induction in Optic Neuritis (VitaDON 2) Recruiting NCT03302585 Phase 2 Vitamin D3;Placebo/Standard of Care Vitamin D3
38 Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial Active, not recruiting NCT02976766 Phase 2 Gypenosides;Placebo
39 A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course Terminated NCT00624468 Phase 2 Atacicept;Placebo matched to atacicept
40 Developing Neuroprotection and Repair Strategies in MS: Phase IIa Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON) Terminated NCT01073813 Phase 2 Minocycline
41 A 48-week, Double-blind, Randomized, Multi-center, Parallel-group Study Comparing Structural Changes in the Retina and Evolution of Visual Function After Immediate Versus Delayed Treatment With Fingolimod in Patients With Acute Demyelinating Optic Neuritis Terminated NCT01757691 Phase 2 Fingolimod 0.5mg/daily;Placebo
42 A Randomised, Double-blind, Placebo-controlled, Single (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BN201 in Healthy Subjects Completed NCT03630497 Phase 1 Comparison of BN201 treatment with Placebo
43 A Randomized, Blinded, Parallel-Group, Phase 1 Study of Pharmacokinetics, Safety and Tolerability of Single Intravenous Doses of BIIB033 (Opicinumab ) Produced by 2 Manufacturing Processes, in Healthy Volunteers Completed NCT02833142 Phase 1 BIIB033 (opicinumab)
44 Lipoic Acid as a Treatment for Acute Optic Neuritis: A Pilot Study Completed NCT01294176 Phase 1 Lipoic Acid
45 Open Label Study of Safety and Tolerability of Rituximab in Neuromyelitis Optica, Recurrent Transverse Myelitis and Recurrent Bilateral Simultaneous Optic Neuritis Completed NCT00501748 Phase 1 Rituximab
46 An Open-label Phase 1b Study of Avastin® (Bevacizumab) for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD). Completed NCT01777412 Phase 1 Bevacizumab
47 Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) Completed NCT02276963 Phase 1 Ublituximab
48 Longitudinal Optic Neuritis Study (LONS) Unknown status NCT00000147 Methylprednisolone;Prednisone
49 Linking Optic Nerve Lesion Length at MRI and the Retinal Axonal Loss at 12 Months From a Clinical Episode of Optic Neuritis Unknown status NCT03651362
50 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Unknown status NCT02886377

Search NIH Clinical Center for Neuritis

Cochrane evidence based reviews: neuritis

Genetic Tests for Neuritis

Anatomical Context for Neuritis

MalaCards organs/tissues related to Neuritis:

40
Brain, Eye, T Cells, Spinal Cord, Retina, Bone, Breast

Publications for Neuritis

Articles related to Neuritis:

(show top 50) (show all 10681)
# Title Authors PMID Year
1
Exome Sequence Analysis Suggests that Genetic Burden Contributes to Phenotypic Variability and Complex Neuropathy. 6
26257172 2015
2
NGLY1 mutation causes neuromotor impairment, intellectual disability, and neuropathy. 6
25220016 2015
3
Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome. 6
25130867 2014
4
Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes. 54 61
18577885 2008
5
Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease. 54 61
16753180 2006
6
Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. 54 61
16519780 2006
7
Guillain-Barré syndrome. 61 54
16271648 2005
8
Sequential expression of chemokines in experimental autoimmune neuritis. 54 61
11024541 2000
9
Pathogenesis of Guillain-Barré syndrome. 54 61
10695718 1999
10
Induction of experimental autoimmune neuritis with peripheral myelin protein-22. 61 54
9798745 1998
11
Clomipramine and imipramine suppress clinical signs and T and B cell response to myelin proteins in experimental autoimmune neuritis in Lewis rats. 61 54
9776709 1998
12
Effect of lipids on the conformation of an antigenic determinant for experimental autoimmune neuritis. 54 61
9584990 1998
13
Antigen therapy eliminates T cell inflammation by apoptosis: effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2. 61 54
9037054 1997
14
The antibody repertoire in experimental allergic neuritis: evidence for PMP-22 as a novel neuritogen. 61 54
8982118 1996
15
Conformation of an antigenic determinant for experimental autoimmune neuritis. 61 54
8694832 1996
16
Human peripheral myelin protein-22 carries the L2/HNK-1 carbohydrate adhesion epitope. 61 54
7693873 1993
17
Pathogenesis of immune-mediated neuropathies. 61 54
8381954 1993
18
Shared T-cell receptor gene usage in experimental allergic neuritis and encephalomyelitis. 61 54
1381167 1992
19
[Immunoregulation disturbance in experimental allergic neuritis. The cellular and humoral mediated immunological damage]. 54 61
1711438 1990
20
Macrophages but not Schwann cells express Ia antigen in experimental autoimmune neuritis. 54 61
2375636 1990
21
Failure of painful eye movements to respond to topical anesthetics supports the diagnosis of optic neuritis. 61
32980224 2021
22
Validation of the Rule of 7's for Identifying Children at Low-risk for Lyme Meningitis. 61
33710975 2021
23
Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder. 61
33188477 2021
24
Unilateral inferior altitudinal visual field defect related to COVID-19. 61
33727475 2021
25
Effects of microRNA-338 Transfection into Sciatic Nerve on Rats with Experimental Autoimmune Neuritis. 61
32915416 2021
26
Anti-MOG-associated demyelinating disorders: two sides of the same coin. 61
33190197 2021
27
Defining the disease course of TNFα blockers-associated Multiple Sclerosis. 61
33647875 2021
28
Which Inner Ear Disorders Lie Behind a Selective Posterior Semicircular Canal Hypofunction on Video Head Impulse Test? 61
33710996 2021
29
[Evidence-based guidelines for diagnosis and treatment of demyelinating optic neuritis in China(2021)]. 61
33721957 2021
30
Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis Presenting as Idiopathic Orbital Inflammatory Syndrome. 61
32108670 2021
31
Sjögren Disease and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis. 61
32235221 2021
32
Expanding the phenotype of MOG antibody-associated disease (MOGAD): half a century of epilepsy and relapsing optic neuritis. 61
33148814 2021
33
Predictors of Visual Acuity and Usefulness of a Treatment Algorithm in Rhinogenous Optic Neuritis. 61
31550936 2021
34
MOG-IgG Among Participants in the Pediatric Optic Neuritis Prospective Outcomes Study. 61
33764379 2021
35
Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. 61
33323985 2021
36
The eyes have it: CNS leukemia presenting as optic neuritis. 61
33394337 2021
37
Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study. 61
33735786 2021
38
Optic neuritis associated with sunitinib. 61
32914245 2021
39
Bilateral myelin oligodendrocyte glycoprotein-related optic neuritis presenting after herpes zoster subunit vaccination. 61
33775591 2021
40
Alterations in the Retinal Vascular Network and Structure in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis: A Longitudinal OCTA Study. 61
33750277 2021
41
Detection of Optic Neuritis on Routine Brain MRI without and with the Assistance of an Image Postprocessing Algorithm. 61
33737263 2021
42
A case of spastic quadriparesis secondary to enteric fever. 61
33657940 2021
43
Return to play rates after ulnar nerve transposition and decompression surgery: a retrospective analysis. 61
33681853 2021
44
Nociceptive signaling of P2X receptors in chronic pain states. 61
33015745 2021
45
Porcine hemagglutinating encephalomyelitis virus infection in vivo and ex vivo. 61
33762411 2021
46
Long-Term Outcomes of Radial Head Arthroplasty for Radial Head Fractures - A Systematic Review at Minimum 8-Year Follow-Up. 61
33812024 2021
47
Neurologic Causes of Thoracic Limb Lameness. 61
33558012 2021
48
Electroactive and antioxidant injectable in-situ forming hydrogels with tunable properties by polyethylenimine and polyaniline for nerve tissue engineering. 61
33445075 2021
49
Trends in Utilization and Cost of Inpatient Spinal Cord Stimulation: Analysis of Data from 2008 to 2014. 61
33359880 2021
50
Retrogradely transmitted α-synuclein is taken up by the endophilin-independent endocytosis in the C. elegans neural circuit. 61
33751935 2021

Variations for Neuritis

ClinVar genetic disease variations for Neuritis:

6 (show top 50) (show all 102)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IARS2 NM_018060.4(IARS2):c.2726C>T (p.Pro909Leu) SNV Pathogenic 156553 rs587783070 GRCh37: 1:220316451-220316451
GRCh38: 1:220143109-220143109
2 PEX6 NM_000287.4(PEX6):c.371T>C (p.Leu124Pro) SNV Pathogenic 869197 GRCh37: 6:42946518-42946518
GRCh38: 6:42978780-42978780
3 PEX6 NM_000287.4(PEX6):c.2356C>T (p.Arg786Trp) SNV Pathogenic 553552 rs267608239 GRCh37: 6:42933788-42933788
GRCh38: 6:42966050-42966050
4 HARS1 NM_002109.6(HARS1):c.616G>T (p.Asp206Tyr) SNV Pathogenic 804285 rs1131040 GRCh37: 5:140057507-140057507
GRCh38: 5:140677922-140677922
5 HARS1 NM_002109.6(HARS1):c.730delG Deletion Pathogenic 804286 rs1581505917 GRCh37: 5:140057005-140057005
GRCh38: 5:140677420-140677420
6 NEFL NM_006158.5(NEFL):c.64C>T (p.Pro22Ser) SNV Pathogenic 14029 rs28928910 GRCh37: 8:24813966-24813966
GRCh38: 8:24956452-24956452
7 HFE NM_000410.3(HFE):c.845G>A (p.Cys282Tyr) SNV Pathogenic 9 rs1800562 GRCh37: 6:26093141-26093141
GRCh38: 6:26092913-26092913
8 CHRNG NM_005199.5(CHRNG):c.256C>T (p.Arg86Cys) SNV Likely pathogenic 397615 rs777219451 GRCh37: 2:233405327-233405327
GRCh38: 2:232540617-232540617
9 NEFL NM_006158.5(NEFL):c.64C>T (p.Pro22Ser) SNV Likely pathogenic 14029 rs28928910 GRCh37: 8:24813966-24813966
GRCh38: 8:24956452-24956452
10 GJB1 NM_000166.6(GJB1):c.218A>G (p.His73Arg) SNV Likely pathogenic 1004038 GRCh37: X:70443775-70443775
GRCh38: X:71223925-71223925
11 COX6A1 NM_004373.4(COX6A1):c.103+1G>C SNV Likely pathogenic 560368 rs377504835 GRCh37: 12:120876033-120876033
GRCh38: 12:120438230-120438230
12 NGLY1 NM_018297.4(NGLY1):c.1533_1536del (p.Asn511fs) Deletion Likely pathogenic 548658 rs765211108 GRCh37: 3:25770699-25770702
GRCh38: 3:25729208-25729211
13 LMNA NM_170707.4(LMNA):c.344A>T (p.Glu115Val) SNV Likely pathogenic 200932 rs794728588 GRCh37: 1:156085053-156085053
GRCh38: 1:156115262-156115262
14 DNAJB5 NM_001135005.3(DNAJB5):c.43C>T (p.Pro15Ser) SNV Likely pathogenic 243086 rs774909609 GRCh37: 9:34990670-34990670
GRCh38: 9:34990673-34990673
15 PMP2 NM_002677.5(PMP2):c.128T>A (p.Ile43Asn) SNV Likely pathogenic 243087 rs879253869 GRCh37: 8:82357170-82357170
GRCh38: 8:81444935-81444935
16 SPTLC3 NM_018327.4(SPTLC3):c.448T>C (p.Trp150Arg) SNV Likely pathogenic 243088 rs755919784 GRCh37: 20:13053048-13053048
GRCh38: 20:13072400-13072400
17 MT-ND4 NC_012920.1:m.11896C>G SNV Uncertain significance 370054 rs1057516065 GRCh37: MT:11896-11896
GRCh38: MT:11896-11896
18 ABCA4 NM_000350.3(ABCA4):c.203C>T (p.Pro68Leu) SNV Uncertain significance 99113 rs62654397 GRCh37: 1:94577093-94577093
GRCh38: 1:94111537-94111537
19 PNPLA6 NM_001166114.2(PNPLA6):c.1205C>T (p.Ser402Leu) SNV Uncertain significance 397619 rs372193709 GRCh37: 19:7606906-7606906
GRCh38: 19:7542020-7542020
20 PRX NM_020956.2(PRX):c.*2540G>A SNV Uncertain significance 397620 rs369505684 GRCh37: 19:40901924-40901924
GRCh38: 19:40396017-40396017
21 KIFBP NM_015634.4(KIFBP):c.167_187dup (p.Asp56_Glu62dup) Duplication Uncertain significance 397616 rs767103634 GRCh37: 10:70748746-70748747
GRCh38: 10:68988990-68988991
22 PHKA1 NM_002637.4(PHKA1):c.1272T>A (p.Asp424Glu) SNV Uncertain significance 397618 rs1060499719 GRCh37: X:71870292-71870292
GRCh38: X:72650442-72650442
23 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33243C>G SNV Uncertain significance 461796 rs140274429 GRCh37: 11:63885468-63885468
GRCh38: 11:64117996-64117996
24 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34761C>G SNV Uncertain significance 530933 rs777177875 GRCh37: 11:63883950-63883950
GRCh38: 11:64116478-64116478
25 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34449C>T SNV Uncertain significance 530935 rs148012979 GRCh37: 11:63884262-63884262
GRCh38: 11:64116790-64116790
26 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33260C>A SNV Uncertain significance 530936 rs143309484 GRCh37: 11:63885451-63885451
GRCh38: 11:64117979-64117979
27 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34743C>T SNV Uncertain significance 530937 rs770193280 GRCh37: 11:63883968-63883968
GRCh38: 11:64116496-64116496
28 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34934G>A SNV Uncertain significance 530938 rs139768227 GRCh37: 11:63883777-63883777
GRCh38: 11:64116305-64116305
29 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33617C>T SNV Uncertain significance 530939 rs150825004 GRCh37: 11:63885094-63885094
GRCh38: 11:64117622-64117622
30 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33852C>G SNV Uncertain significance 530941 rs138445479 GRCh37: 11:63884859-63884859
GRCh38: 11:64117387-64117387
31 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33881C>T SNV Uncertain significance 565723 rs767022154 GRCh37: 11:63884830-63884830
GRCh38: 11:64117358-64117358
32 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33604C>A SNV Uncertain significance 566560 rs1395376914 GRCh37: 11:63885107-63885107
GRCh38: 11:64117635-64117635
33 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33719C>T SNV Uncertain significance 568577 rs769032516 GRCh37: 11:63884992-63884992
GRCh38: 11:64117520-64117520
34 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34898_517+34918del Deletion Uncertain significance 571356 rs1565240655 GRCh37: 11:63883793-63883813
GRCh38: 11:64116321-64116341
35 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33243C>T SNV Uncertain significance 575806 rs140274429 GRCh37: 11:63885468-63885468
GRCh38: 11:64117996-64117996
36 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34250T>A SNV Uncertain significance 577882 rs1565241569 GRCh37: 11:63884461-63884461
GRCh38: 11:64116989-64116989
37 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34535G>A SNV Uncertain significance 579757 rs756250929 GRCh37: 11:63884176-63884176
GRCh38: 11:64116704-64116704
38 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33906T>G SNV Uncertain significance 640772 rs1590933528 GRCh37: 11:63884805-63884805
GRCh38: 11:64117333-64117333
39 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34305T>C SNV Uncertain significance 643512 rs1590932597 GRCh37: 11:63884406-63884406
GRCh38: 11:64116934-64116934
40 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33198G>A SNV Uncertain significance 645543 rs375487485 GRCh37: 11:63885513-63885513
GRCh38: 11:64118041-64118041
41 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34236G>A SNV Uncertain significance 647420 rs756527574 GRCh37: 11:63884475-63884475
GRCh38: 11:64117003-64117003
42 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33328C>A SNV Uncertain significance 658157 rs1590934834 GRCh37: 11:63885383-63885383
GRCh38: 11:64117911-64117911
43 MYBPC3 NM_000256.3(MYBPC3):c.3614G>A (p.Arg1205Gln) SNV Uncertain significance 181014 rs730880596 GRCh37: 11:47354130-47354130
GRCh38: 11:47332579-47332579
44 KCNJ10 NM_002241.5(KCNJ10):c.967T>C (p.Tyr323His) SNV Uncertain significance 816536 rs1571265188 GRCh37: 1:160011356-160011356
GRCh38: 1:160041566-160041566
45 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34501G>T SNV Uncertain significance 842634 GRCh37: 11:63884210-63884210
GRCh38: 11:64116738-64116738
46 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+33197C>T SNV Uncertain significance 845837 GRCh37: 11:63885514-63885514
GRCh38: 11:64118042-64118042
47 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34527G>A SNV Uncertain significance 948270 GRCh37: 11:63884184-63884184
GRCh38: 11:64116712-64116712
48 FLRT1 , MACROD1 NM_014067.4(MACROD1):c.517+34391G>A SNV Uncertain significance 957887 GRCh37: 11:63884320-63884320
GRCh38: 11:64116848-64116848
49 FLRT1 , MACROD1 NM_013280.5(FLRT1):c.389G>A (p.Arg130Gln) SNV Uncertain significance 1002428 GRCh37: 11:63884128-63884128
GRCh38: 11:64116656-64116656
50 FLRT1 , MACROD1 NM_013280.5(FLRT1):c.2006T>C (p.Ile669Thr) SNV Uncertain significance 1003977 GRCh37: 11:63885745-63885745
GRCh38: 11:64118273-64118273

Expression for Neuritis

Search GEO for disease gene expression data for Neuritis.

Pathways for Neuritis

Pathways related to Neuritis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.13 TNF CCL5 CCL4
2 10.93 PMP22 MPZ MBP GJB1
3 10.82 TNF CCL5 CCL4

GO Terms for Neuritis

Cellular components related to Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.8 PMP2 MPZ MBP

Biological processes related to Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.67 TNF NEFL MBP CCL5
2 response to virus GO:0009615 9.61 TNF CCL5 CCL4
3 chemical synaptic transmission GO:0007268 9.56 PMP22 MPZ MBP CHRNG
4 eosinophil chemotaxis GO:0048245 9.4 CCL5 CCL4
5 negative regulation by host of viral transcription GO:0043922 9.32 CCL5 CCL4
6 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.16 TNF MBP
7 positive regulation of natural killer cell chemotaxis GO:2000503 8.96 CCL5 CCL4
8 response to toxic substance GO:0009636 8.92 NEFL MBP CCL5 CCL4

Molecular functions related to Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR5 chemokine receptor binding GO:0031730 8.96 CCL5 CCL4
2 CCR1 chemokine receptor binding GO:0031726 8.62 CCL5 CCL4

Sources for Neuritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....